Sign in
Taking people in AustriaPhase 2

Tests an antihistamine with immunotherapy in advanced non-small cell lung cancer

Tests an antihistamine added to immunotherapy in adults with advanced lung cancer.

Key facts

Who runs it
Medical University Of Vienna
Where
Vienna, AustriaSee the site
Registry title
H1-antihistaminE treatment in combiNation with immunotHerapy in pAtieNts with advanced non small cell lung canCEr: A single- center phase -ENHANCE
Status
Recruiting
Phase
Phase 2
People taking part
9 people, planned
Started
13 Oct 2022
Planned end
29 Aug 2026
Type of study
Interventional
Record updated
10 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. They have not had treatment for the spread and are planned to get pembrolizumab alone.

Age
18 years or older
Sex
All sexes can join
Disease stage
Squamous or non-squamous non-small cell lung cancer, confirmed by tissue tests. The cancer has spread, cannot be removed by surgery, and can be measured on scans (RECIST 1.1). ECOG-PS 0-2, KPS >70%.
Earlier treatment
No earlier systemic therapy for the spread of the cancer. Radiotherapy or chemotherapy before or after surgery is allowed with a washout period: 4 weeks after major surgery or radiation, 2 weeks after chemotherapy or systemic steroids. Planned to get pembrolizumab alone.

Main reasons for not taking part

  • Earlier anti-CTLA4 or PD-1/PD-L1 treatment for early-stage lung cancer
  • Known autoimmune disease (a few exceptions), known HIV, or hepatitis B or C
  • Another cancer within the last 3 years (a few skin and cervical exceptions)
  • Pregnant or breastfeeding women
  • Allergy to fexofenadine hydrochloride or related products

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Capability of understanding the purpose of the study and have given written informed consent. • Histologically confirmed squamous or non-squamous NSCLC • Radiologically documented metastatic unresectable disease • Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST version 1.1) • No previous systemic therapy for metastatic disease • Patients who are planned to receive pembrolizumab monotherapy in routine indication and according to the marketing authorisation • Patient with a history of adequately treated, asymptomatic CNS metastases are eligible, provided they meet all of the following criteria: Only supratentorial metastases allowed (i.e., no metastases to midbrain, pons, medulla or spinal cord). No ongoing requirement for corticosteroids as therapy for CNS disease; anticonvulsants at a stable dose allowed. • Age ≥ 18 years • ECOG-PS 0-2, KPS >70% • Adequate bone-marrow, liver and kidney function – except of a tumor-associated dysfunction due to metastatic NSCLC disease • No previous systemic therapy for metastatic disease. Patients who received prior radio- and/or chemotherapy in neoadjuvant or adjuvant indications before study inclusion are allowed in consideration of an adequate washout period before the enrolment. Adequate treatment washout period before enrolment, defined as: - Major Surgery: ≥4 weeks - Radiation therapy: ≥4 weeks - Chemotherapy: ≥2 weeks - Systemic steroid-treatment: ≥2 weeks • Patient must be able to tolerate therapy • Women of childbearing potential must have a negative pregnancy test at screening, pregnancy testing must be performed within 7 days before first administration of IMP. Approved methods of birth control must be used in women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, from study start to the last dose of protocol therapy. Adequate contraception defined as hormonal birth control, intrauterine device, double barrier method or total abstinence

Who cannot take part

  • Patients who received anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway for early-stage NSCLC • A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs • Patients requiring concomitant use of chronic systemic (IV or oral) corticosteroids higher than 10mg prednisolone per day or other immunosuppressive medications except for managing adverse events (inhaled steroids or intra articular steroid injections are permitted in this study) • Use of any investigational agent within 28 days prior to initiation of study treatment • History of malignancy other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 3 years • Presence of history of drug hypersensitivity of fexofenadine hydrochloride or other related products • Known autoimmune disease (with the exception of residual hypothyroidism on an autoimmune basis, diabetes mellitus type 1, psoriasis not requiring systemic treatment) • Known HIV • Hepatitis B or C infection • Pregnant or lactating women • Male subjects unable or unwilling to use adequate contraception methods • Patients with known substance abuse or any other medical conditions such as clinically significant neurological or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results • Patients who are unable to swallow

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Which best describes your lung cancer?
  • Has the cancer spread to other parts of the body, or is it too advanced to be removed by surgery?

Where in Austria

  • Medical University of ViennaVienna, AustriaTaking people

About the trial

What the trial wants to find out

Best objective response rate according to RECIST 1.1

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
H1-antihistaminE treatment in combiNation with immunotHerapy in pAtieNts with advanced non small cell lung canCEr: A single- center phase II trial-ENHANCE
Plain-language title
Tests an antihistamine with immunotherapy in advanced non-small cell lung cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2024-518633-28-00, who can take part
Record updated
10 December 2024